Evolving Biomarkers in Osteoarthritis

ABSTRACT

Osteoarthritis (OA) is one of the most debilitating diseases affecting mankind with severe financial and emotional consequences. The heterogeneity of the human population, lack of complete understanding of the OA disease process, and the slow progressive nature of the disease characterized by prolonged periods of nonsymptomatic, degenerative changes has hampered development of ideal diagnostic and prognostic portfolios. The difficulties associated with early OA diagnosis by exclusively radiographic techniques has propelled a need to identify specific biomarkers for rapid and effective early OA diagnosis, better patient prognosis, and for monitoring the efficacy of pharmacological interventions to the disease process. This review highlights some of the biochemical biomarkers in current use in OA, their applications and limitations. Investigation of single nucleotide polymorphisms as genetic biomarkers and the application of technologies such as lipidomics and metabolomics to OA are generating potentially additional biomarkers that could be helpful for detecting early OA phenomena in humans.

Biomarker - osteoarthritis - collagen degradation - early osteoarthritis - single nucleotide polymorphism

REFERENCES

• 1 Kraus V B. Waiting for action on the osteoarthritis front.  Curr Drug Targets. 2010;  11 (5) 518-520
• 2 Kraus V B, Nevitt M, Sandell L J. Summary of the OA biomarkers workshop 2009—biochemical biomarkers: biology, validation, and clinical studies.  Osteoarthritis Cartilage. 2010;  18 (6) 742-745
• 3 Kraus V B, Burnett B, Coindreau J OARSI FDA Osteoarthritis Biomarkers Working Group et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.  Osteoarthritis Cartilage. 2011;  19 (5) 515-542
• 4 Sugiyama S, Itokazu M, Suzuki Y, Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis.  Ann Rheum Dis. 2003;  62 (1) 27-32
• 5 Sandell L J, Morris N, Robbins J R, Goldring M B. Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide.  J Cell Biol. 1991;  114 (6) 1307-1319
• 6 Nemirovskiy O V, Sunyer T, Aggarwal P, Abrams M, Hellio Le Graverand M P, Mathews W R. Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis.  Osteoarthritis Cartilage. 2008;  16 (12) 1494-1500
• 7 Christgau S, Garnero P, Fledelius C et al.. Collagen type II C-telopeptide fragments as an index of cartilage degradation.  Bone. 2001;  29 (3) 209-215
• 8 Freeston J E, Garnero P, Wakefield R J, Hensor E M, Conaghan P G, Emery P. Urinary type II collagen C-terminal peptide is associated with synovitis and predicts structural bone loss in very early inflammatory arthritis.  Ann Rheum Dis. 2011;  70 (2) 331-333
• 9 Bay-Jensen A C, Andersen T L, Charni-Ben Tabassi N et al.. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage.  Osteoarthritis Cartilage. 2008;  16 (5) 615-623
• 10 Kraus V B, Kepler T B, Stabler T, Renner J, Jordan J. First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis.  PLoS ONE. 2010;  5 (3) e9739
• 11 Garnero P, Ayral X, Rousseau J C et al.. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.  Arthritis Rheum. 2002;  46 (10) 2613-2624
• 12 Manicourt D H, Azria M, Mindeholm L, Thonar E J, Devogelaer J P. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis.  Arthritis Rheum. 2006;  54 (10) 3205-3211
• 13 Christgau S, Henrotin Y, Tankó L B et al.. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate.  Clin Exp Rheumatol. 2004;  22 (1) 36-42
• 14 Nemirovskiy O V, Dufield D R, Sunyer T, Aggarwal P, Welsch D J, Mathews W R. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo.  Anal Biochem. 2007;  361 (1) 93-101
• 15 Deberg M A, Labasse A H, Collette J, Seidel L, Reginster J Y, Henrotin Y E. One-year increase of Coll 2–1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression.  Osteoarthritis Cartilage. 2005;  13 (12) 1059-1065
• 16 Deberg M, Labasse A, Christgau S et al.. New serum biochemical markers (Coll 2–1 and Coll 2–1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis.  Osteoarthritis Cartilage. 2005;  13 (3) 258-265
• 17 Sandy J D, Flannery C R, Neame P J, Lohmander L S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain.  J Clin Invest. 1992;  89 (5) 1512-1516
• 18 Swearingen C A, Carpenter J W, Siegel R et al.. Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine.  Osteoarthritis Cartilage. 2010;  18 (9) 1150-1158
• 19 Duan Y, Hao D, Li M et al.. Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis.  Rheumatol Int. 2011;  January 19 (Epub ahead of print)
• 20 Hao D, Li M, Wu Z, Duan Y, Li D, Qiu G. Synovial fluid level of adiponectin correlated with levels of aggrecan degradation markers in osteoarthritis.  Rheumatol Int. 2010;  May 13 (Epub ahead of print)
• 21 Scuderi G J, Golish S R, Cook F F, Cuellar J M, Bowser R P, Hanna L S. Identification of a novel fibronectin-aggrecan complex in the synovial fluid of knees with painful meniscal injury.  J Bone Joint Surg Am. 2011;  93 (4) 336-340
• 22 Mazzuca S A, Poole A R, Brandt K D, Katz B P, Lane K A, Lobanok T. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis.  J Rheumatol. 2006;  33 (6) 1147-1151
• 23 Uebelhart D, Thonar E J, Delmas P D, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study.  Osteoarthritis Cartilage. 1998;  6 (Suppl A) 39-46
• 24 Garnero P, Delmas P D. Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers.  Curr Opin Rheumatol. 2004;  16 (4) 428-434
• 25 Marx R E, Cillo Jr J E, Ulloa J J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.  J Oral Maxillofac Surg. 2007;  65 (12) 2397-2410
• 26 Bingham III C O, Buckland-Wright J C, Garnero P et al.. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.  Arthritis Rheum. 2006;  54 (11) 3494-3507
• 27 Spector T D, Conaghan P G, Buckland-Wright J C et al.. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173].  Arthritis Res Ther. 2005;  7 (3) R625-R633
• 28 Ishijima M, Watari T, Naito K et al.. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis.  Arthritis Res Ther. 2011;  13 (1) R22
• 29 Berry P A, Maciewicz R A, Cicuttini F M, Jones M D, Hellawell C J, Wluka A E. Markers of bone formation and resorption identify subgroups of patients with clinical knee osteoarthritis who have reduced rates of cartilage loss.  J Rheumatol. 2010;  37 (6) 1252-1259
• 30 Gineyts E, Garnero P, Delmas P D. Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation.  Rheumatology (Oxford). 2001;  40 (3) 315-323
• 31 Jordan K M, Syddall H E, Garnero P et al.. Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men.  Ann Rheum Dis. 2006;  65 (7) 871-877
• 32 Gineyts E, Mo J A, Ko A et al.. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis.  Ann Rheum Dis. 2004;  63 (7) 857-861
• 33 Kokebie R, Aggarwal R, Lidder S et al.. The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors.  Arthritis Res Ther. 2011;  13 (2) R50
• 34 Andersson M L, Petersson I F, Karlsson K E et al.. Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis.  Ann Rheum Dis. 2006;  65 (11) 1490-1494
• 35 Kong S Y, Stabler T V, Criscione L G, Elliott A L, Jordan J M, Kraus V B. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis.  Arthritis Rheum. 2006;  54 (8) 2496-2504
• 36 Criscione L G, Elliott A L, Stabler T, Jordan J M, Pieper C F, Kraus V B. Variation of serum hyaluronan with activity in individuals with knee osteoarthritis.  Osteoarthritis Cartilage. 2005;  13 (9) 837-840
• 37 Qvist P, Christgau S, Pedersen B J, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting.  Bone. 2002;  31 (1) 57-61
• 38 Ikegawa S. Genetic analysis of skeletal dysplasia: recent advances and perspectives in the post-genome-sequence era.  J Hum Genet. 2006;  51 (7) 581-586
• 39 Briggs M D, Hoffman S M, King L M et al.. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene.  Nat Genet. 1995;  10 (3) 330-336
• 40 Czarny-Ratajczak M, Lohiniva J, Rogala P et al.. A mutation in COL9A1 causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity.  Am J Hum Genet. 2001;  69 (5) 969-980
• 41 Chapman K L, Mortier G R, Chapman K, Loughlin J, Grant M E, Briggs M D. Mutations in the region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia.  Nat Genet. 2001;  28 (4) 393-396
• 42 Tiller G E, Rimoin D L, Murray L W, Cohn D H. Tandem duplication within a type II collagen gene (COL2A1) exon in an individual with spondyloepiphyseal dysplasia.  Proc Natl Acad Sci U S A. 1990;  87 (10) 3889-3893
• 43 Miyamoto Y, Mabuchi A, Shi D et al.. A functional polymorphism in the 5′ UTR of GDF5 is associated with susceptibility to osteoarthritis.  Nat Genet. 2007;  39 (4) 529-533
• 44 Daans M, Luyten F P, Lories R J. GDF5 deficiency in mice is associated with instability-driven joint damage, gait and subchondral bone changes.  Ann Rheum Dis. 2011;  70 (1) 208-213
• 45 Chapman K, Takahashi A, Meulenbelt I et al.. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5′ UTR of GDF5 with osteoarthritis susceptibility.  Hum Mol Genet. 2008;  17 (10) 1497-1504
• 46 Kizawa H, Kou I, Iida A et al.. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis.  Nat Genet. 2005;  37 (2) 138-144
• 47 Stern A G, de Carvalho M R, Buck G A I-NODAL Network et al. Association of erosive hand osteoarthritis with a single nucleotide polymorphism on the gene encoding interleukin-1 beta.  Osteoarthritis Cartilage. 2003;  11 (6) 394-402
• 48 Vaes R B, Rivadeneira F, Kerkhof J M et al.. Genetic variation in the GDF5 region is associated with osteoarthritis, height, hip axis length and fracture risk: the Rotterdam study.  Ann Rheum Dis. 2009;  68 (11) 1754-1760
• 49 Panoutsopoulou K, Southam L, Elliott K S arcOGEN Consortium et al. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study.  Ann Rheum Dis. 2011;  70 (5) 864-867
• 50 Castro-Perez J M, Kamphorst J, DeGroot J et al.. Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients.  J Proteome Res. 2010;  9 (5) 2377-2389
• 51 Zhai G, Wang-Sattler R, Hart D J et al.. Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis.  Ann Rheum Dis. 2010;  69 (6) 1227-1231